Due to our extensive coverage of the AACR21 conference, we will not include any spotlights this week. We'll bring them back next Wednesday!
There are no spotlights this week
SpotlightDue to our extensive coverage of the AACR21 conference, we will not include any spotlights this week. We'll bring them back next Wednesday!
In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)
(1) Wang Y (2) Zhou Y (3) Cao S (4) Sun Y (5) Dong Z (6) Li C (7) Wang H (8) Yao Y (9) Yu H (10) Song X (11) Li M (12) Wang J (13) Wei M (14) Yang G (15) Yang C
(1) Wang Y (2) Zhou Y (3) Cao S (4) Sun Y (5) Dong Z (6) Li C (7) Wang H (8) Yao Y (9) Yu H (10) Song X (11) Li M (12) Wang J (13) Wei M (14) Yang G (15) Yang C
Author Info: (1) The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, PR China. (2) The State Key Laboratory of Medicinal Chemical Bio
Author Info: (1) The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, PR China. (2) The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, PR China. (3) The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, PR China. (4) The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, PR China. (5) The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, PR China. (6) The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, PR China. (7) The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, PR China. (8) The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, PR China. (9) Tianjin Pacific Chemical & Pharmaceutical Co., LTD, Tianjin 300350, PR China. (10) Tianjin Pacific Chemical & Pharmaceutical Co., LTD, Tianjin 300350, PR China. (11) Cangzhou Institutes for Food and Drug Control, Cangzhou 061000, PR China. (12) Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, PR China. Electronic address: jwang05@tmu.edu.cn. (13) The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, PR China. Electronic address: mingmingshengwu@163.com. (14) The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, PR China. Electronic address: Guang.yang@nankai.edu.cn. (15) The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, PR China.
Citation: Bioorg Chem 2021 Mar 19 111:104833 Epub03/19/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33839580
Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer
(1) Thomas PL (2) Groves SM (3) Zhang YK (4) Li J (5) Gonzalez-Ericsson P (6) Sivagnanam S (7) Betts CB (8) Chen HC (9) Liu Q (10) Lowe C (11) Chen H (12) Boyd KL (13) Kopparapu PR (14) Yan Y (15) Coussens LM (16) Quaranta V (17) Tyson DR (18) Iams W (19) Lovly CM
(1) Thomas PL (2) Groves SM (3) Zhang YK (4) Li J (5) Gonzalez-Ericsson P (6) Sivagnanam S (7) Betts CB (8) Chen HC (9) Liu Q (10) Lowe C (11) Chen H (12) Boyd KL (13) Kopparapu PR (14) Yan Y (15) Coussens LM (16) Quaranta V (17) Tyson DR (18) Iams W (19) Lovly CM
Author Info: (1) Department of Microbiology, Immunology, and Physiology, School of Medicine; School of Graduate Studies and Research, Meharry Medical College, Nashville, TN, USA. (2) Department
Author Info: (1) Department of Microbiology, Immunology, and Physiology, School of Medicine; School of Graduate Studies and Research, Meharry Medical College, Nashville, TN, USA. (2) Department of Biochemistry, Vanderbilt University, Nashville, TN, USA. (3) Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. (4) Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA. (5) Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA. (6) Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. (7) Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. (8) Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA. (9) Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA. (10) Department of Pathology, Immunology, and Microbiology, Vanderbilt University Medical Center, Nashville, TN, USA. (11) Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA. (12) Department of Pathology, Immunology, and Microbiology, Vanderbilt University Medical Center, Nashville, TN, USA. (13) Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. (14) Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. (15) Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. (16) Department of Biochemistry, Vanderbilt University, Nashville, TN, USA. (17) Department of Biochemistry, Vanderbilt University, Nashville, TN, USA. (18) Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. (19) School of Graduate Studies and Research, Meharry Medical College, Nashville, TN, USA; Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: christine.lovly@vumc.org.
Citation: J Thorac Oncol 2021 Apr 8 Epub04/08/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33839362
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
(1) Neijssen J (2) Cardoso RMF (3) Chevalier KM (4) Wiegman L (5) Valerius T (6) Anderson GM (7) Moores SL (8) Schuurman J (9) Parren PWHI (10) Strohl WR (11) Chiu ML
(1) Neijssen J (2) Cardoso RMF (3) Chevalier KM (4) Wiegman L (5) Valerius T (6) Anderson GM (7) Moores SL (8) Schuurman J (9) Parren PWHI (10) Strohl WR (11) Chiu ML
Author Info: (1) Genmab, Utrecht, The Netherlands. (2) Janssen Research & Development, Spring House, PA, USA. (3) Janssen Research & Development, Spring House, PA, USA. (4) Genmab, Utrecht, The
Author Info: (1) Genmab, Utrecht, The Netherlands. (2) Janssen Research & Development, Spring House, PA, USA. (3) Janssen Research & Development, Spring House, PA, USA. (4) Genmab, Utrecht, The Netherlands. (5) Section for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University and University Hospital Schleswig-Holstein, Kiel, Germany. (6) Janssen Research & Development, Spring House, PA, USA. (7) Janssen Research & Development, Spring House, PA, USA. (8) Genmab, Utrecht, The Netherlands. (9) Genmab, Utrecht, The Netherlands. (10) Janssen Research & Development, Spring House, PA, USA. (11) Janssen Research & Development, Spring House, PA, USA. Electronic address: markchiu03@gmail.com.
Citation: J Biol Chem 2021 Apr 8 100641 Epub04/08/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33839159
(1) Lutz MB (2) Eckert IN
(1) Lutz MB (2) Eckert IN
Author Info: (1) Institute for Virology and Immunobiology, University of Wrzburg, Wrzburg, Germany. Electronic address: m.lutz@vim.uni-wuerzburg.de. (2) Institute for Virology and Immunobiolo
Author Info: (1) Institute for Virology and Immunobiology, University of Wrzburg, Wrzburg, Germany. Electronic address: m.lutz@vim.uni-wuerzburg.de. (2) Institute for Virology and Immunobiology, University of Wrzburg, Wrzburg, Germany.
Citation: Cell Immunol 2021 Mar 29 364:104347 Epub03/29/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33838447
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression
(1) Ochi N (2) Ichihara E (3) Takigawa N (4) Harada D (5) Inoue K (6) Shibayama T (7) Hosokawa S (8) Kishino D (9) Harita S (10) Oda N (11) Hara N (12) Hotta K (13) Maeda Y (14) Kiura K
(1) Ochi N (2) Ichihara E (3) Takigawa N (4) Harada D (5) Inoue K (6) Shibayama T (7) Hosokawa S (8) Kishino D (9) Harita S (10) Oda N (11) Hara N (12) Hotta K (13) Maeda Y (14) Kiura K
Author Info: (1) Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan. (2) Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan. Elec
Author Info: (1) Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan. (2) Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan. Electronic address: ichiha-e@md.okayama-u.ac.jp. (3) Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan. (4) Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Japan. (5) Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Japan. (6) Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan. (7) Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Japan. (8) Department of Respiratory Medicine, Himeji Red Cross Hospital, Japan. (9) Department of Internal Medicine, Okayama Saiseikai General Hospital, Japan. (10) Department of Internal Medicine, Fukuyama City Hospital, Japan. (11) Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan. (12) Center for Innovative Clinical Medicine, Okayama University Hospital, Japan. (13) Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan. (14) Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Citation: Eur J Cancer 2021 Apr 7 149:73-81 Epub04/07/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33838391
High-throughput identification of conditional MHCI ligands and scaled-up production of conditional MHCI complexes
(1) Darwish M (2) Wichner S (3) Li J (4) Chang JC (5) Tam C (6) Franke Y (7) Li H (8) Chan P (9) Blanchette C
(1) Darwish M (2) Wichner S (3) Li J (4) Chang JC (5) Tam C (6) Franke Y (7) Li H (8) Chan P (9) Blanchette C
Author Info: (1) Genentech Inc, Protein Chemistry. (2) Genentech Inc, Protein Chemistry. (3) Genentech Inc, Biochemical and Cellular Pharmacology. (4) Genentech Inc, Protein Chemistry. (5) Gene
Author Info: (1) Genentech Inc, Protein Chemistry. (2) Genentech Inc, Protein Chemistry. (3) Genentech Inc, Biochemical and Cellular Pharmacology. (4) Genentech Inc, Protein Chemistry. (5) Genentech Inc, BioMolecular Resources. (6) Genentech Inc, BioMolecular Resources. (7) Genentech Inc, Protein Chemistry. (8) Genentech Inc, Biochemical and Cellular Pharmacology. (9) Genentech Inc.
Citation: Protein Sci 2021 Apr 11 Epub04/11/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33840137
Tags:
Exercise training improves tumor control by increasing CD8+ T-cell infiltration via CXCR3 signaling and sensitizes breast cancer to immune checkpoint blockade
(1) Gomes-Santos IL (2) Amoozgar Z (3) Kumar AS (4) Ho WW (5) Roh K (6) Talele NP (7) Curtis H (8) Kawaguchi K (9) Jain RK (10) Fukumura D
(1) Gomes-Santos IL (2) Amoozgar Z (3) Kumar AS (4) Ho WW (5) Roh K (6) Talele NP (7) Curtis H (8) Kawaguchi K (9) Jain RK (10) Fukumura D
Author Info: (1) Radiation Oncology, Massachusetts General Hospital & Harvard Medical School. (2) Massachusetts General Hospital. (3) Radiation Oncology, Massachusetts General Hospital & Harvar
Author Info: (1) Radiation Oncology, Massachusetts General Hospital & Harvard Medical School. (2) Massachusetts General Hospital. (3) Radiation Oncology, Massachusetts General Hospital & Harvard Medical School. (4) Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital. (5) Radiation Oncology, Massachusetts General Hospital & Harvard Medical School. (6) Cancer Center, Massachusetts General Hospital. (7) Radiation Oncology, Massachusetts General Hospital & Harvard Medical School. (8) Department of Breast Surgery, Kyoto University. (9) Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School. (10) Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School dai@steele.mgh.harvard.edu.
Citation: Cancer Immunol Res 2021 Apr 10 Epub04/10/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33839688
Yeasts as a promising delivery platform for DNA and RNA vaccines
(1) Silva AJD (2) de Macdo LS (3) Leal LRS (4) de Jesus ALS (5) Freitas AC
(1) Silva AJD (2) de Macdo LS (3) Leal LRS (4) de Jesus ALS (5) Freitas AC
Author Info: (1) Laboratrio de Estudos Moleculares e Terapia Experimental, Department of Genetics, Federal University of Pernambuco, Av. Prof. Moraes Rgo, 1235, Cidade Universitaria, Recife,
Author Info: (1) Laboratrio de Estudos Moleculares e Terapia Experimental, Department of Genetics, Federal University of Pernambuco, Av. Prof. Moraes Rgo, 1235, Cidade Universitaria, Recife, Pernambuco, Brazil. (2) Laboratrio de Estudos Moleculares e Terapia Experimental, Department of Genetics, Federal University of Pernambuco, Av. Prof. Moraes Rgo, 1235, Cidade Universitaria, Recife, Pernambuco, Brazil. (3) Laboratrio de Estudos Moleculares e Terapia Experimental, Department of Genetics, Federal University of Pernambuco, Av. Prof. Moraes Rgo, 1235, Cidade Universitaria, Recife, Pernambuco, Brazil. (4) Laboratrio de Estudos Moleculares e Terapia Experimental, Department of Genetics, Federal University of Pernambuco, Av. Prof. Moraes Rgo, 1235, Cidade Universitaria, Recife, Pernambuco, Brazil. (5) Laboratrio de Estudos Moleculares e Terapia Experimental, Department of Genetics, Federal University of Pernambuco, Av. Prof. Moraes Rgo, 1235, Cidade Universitaria, Recife, Pernambuco, Brazil.
Citation: FEMS Yeast Res 2021 Apr 7 21: Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33837785
T cell memory in tissues
(1) van Gisbergen KPJM (2) Zens KD (3) Mnz C
(1) van Gisbergen KPJM (2) Zens KD (3) Mnz C
Author Info: (1) Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Department of Experimental Immunol
Author Info: (1) Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. (2) Viral Immunobiology, University of Zurich, Zurich, Switzerland. Epidemiology, Biostatistics and Prevention Institute, Department of Public and Global Health, University of Zurich, Zurich, Switzerland. Department of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland. (3) Viral Immunobiology, University of Zurich, Zurich, Switzerland.
Citation: Eur J Immunol 2021 Apr 10 Epub04/10/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33837521
Comments on the ambiguity of selected surface markers, signaling pathways and omics profiles hampering the identification of myeloid-derived suppressor cells